It is a likely reason why the weight loss and liver fat numbers in trials look stronger than older single- or dual-pathway compounds
to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease
Absorption rates can vary slightly depending on: Injection site Abdominal injections may be absorbed slightly faster than thigh injections Injection depth Proper subcutaneous technique ensures consistent absorption Site rotation Regular rotation prevents lipohypertrophy (fatty lumps) that can affect absorption Renal and Hepatic Function The impact of kidney and liver function varies by medication: Exenatide is contraindicated if your kidney function is severely reduced (eGFR/CrCl below 30 mL/min) Lixisenatide is not recommended in severe renal impairment (eGFR below 15 mL/min) Semaglutide, dulaglutide, and liraglutide generally don't require dose adjustment for mild to moderate kidney or liver impairment, but should be used with caution in severe impairment Drug Interactions GLP-1 medications can affect the absorption of oral medications due to delayed gastric emptying
GI side effects appear dose-dependent, tend to be mild to moderate, and often improve as the body adjusts during dose escalation
So that's what we're going to get into In the rest of this letter, StayCurious Metabolism premium members, we will dive into: My Experiment Personal experience Biomarkers Resolving the Retatrutide Paradoxes Why some people get hungrier while others lose their appetite Why some preserve muscle while others lose it We will address the trillion-dollar question: Should you
%20(1).png)
